|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||||||
  Headache: The Journal of Head and Face PainVolume 37 Issue 7, Pages 437 - 442 Published Online: 25 Jun 2002 © 2010 American Headache Society Published on behalf of the American Headache Society
Abstract | Full Text: PDF (Size: 94K) | Related Articles | Citation Tracking  Presented in part at the 97th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Orlando, Fla, March 1996. Copyright American Headache Society KEYWORDS methylergonovine maleate • cluster • methysergide ABSTRACTMethylergonovine maleate (Methergine®), an ergot derivative with vasoconstrictive properties, has been cited as an effective treatment for vascular headaches. Few studies are available to support its use in headache management. An uncontrolled pilot study of 20 episodic cluster headache patients confirmed its effectiveness and tolerability as an adjunct cluster headache prophylactic. Decreased headache frequency was reported by 19 of 20 patients (95%), and 15 of 20 patients (75%) reported decreased intensity of headaches within 1 week of initiating therapy. A review of methylergonovine's pharmacokinetic, molecular, and tolerability profile clarifies its mechanisms and clinical role in headache management. Accepted for publication March 4, 1997. | 
|
